Wenxiang Wang

机构：Central South University, Peking University, Peking University Cancer Hospital, Hunan Cancer Hospital, Peking University People's Hospital

发表论文 41 篇 · 总被引 624 次 · h-index 12

代表论文

• Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial (2024 · The Lancet Respiratory Medicine · 被引 122)
• Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study. (2023 · Journal of Clinical Oncology · 被引 89)
• Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study (2024 · The Lancet Oncology · 被引 61)
• What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? (2021 · Frontiers in Immunology · 被引 46)
• Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. (2023 · Journal of Clinical Oncology · 被引 42)
• Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer (2023 · Frontiers in Immunology · 被引 40)